Core Insights - The Qingdao Free Trade Zone has strategically developed the life and health industry, with 69 projects, 5 provincial-level R&D institutions, and over 3,700 talents in the sector [1] Group 1: Industry Development - The Qingdao Free Trade Zone has established a strong foundation for the life and health industry, focusing on basic research, applied research, and industrial transformation [1] - The region has successfully introduced over 10 biopharmaceutical companies, leveraging leading enterprises to create a 288,000 square meter development platform for the life and health industry [1] Group 2: Technological Innovation - Breakthroughs in various cutting-edge technology fields have been achieved, including over 100 authorized invention patents in molecular breeding and more than 200 PCT international invention patents [1] - The global first immune anti-tumor marine polysaccharide new drug BG136 is expected to release its phase II clinical report in March [1] Group 3: Future Plans - The Qingdao Free Trade Zone aims to introduce 18 globally leading projects in exosome and cell transformation applications by 2025, doubling the number of projects within two years [1] - The focus will be on exploring application scenarios and optimizing the life and health industry ecosystem to better serve enterprise development [2]

Group 1 - The Qingdao Free Trade Zone has strategically planned the development of the life and health industry, achieving significant progress with 69 projects and the establishment of 5 provincial-level research institutions [1] - The industry has attracted over 3,700 talents and has been recognized for its potential in gene technology, with the gene technology industry cluster included in Shandong Province's future industry clusters [1] - The global first immune anti-tumor marine polysaccharide new drug BG136 is expected to release its phase II clinical report in March, showcasing the collaborative innovation efforts of various research institutions [1] Group 2 - The Qingdao Free Trade Zone has made breakthroughs in multiple cutting-edge technology fields, with over 100 invention patents authorized and more than 200 PCT international invention patents authorized [1] - Three leading enterprises, Guoxin Pharmaceutical, BGI, and Qingyuan, have established operations in the zone, which has developed a 288,000 square meter facility for the life and health industry [1] - The zone aims to introduce 18 new projects related to exosomes and cell transformation applications by 2025, indicating a doubling of project numbers within two years [1][2]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 责任编辑：宋雅芳 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 近日，中邮证券发布研究报告，维持对"AI+医疗"行业"强于大市"的评级，认为该行业在政策与产业共 振下正迎来加速发展。华大智造、华大基因、晶泰控股、英矽智能、联影智能、鹰瞳科技等多家行业内 企业获关注。 近日，中邮证券发布研究报告，维持对"AI+医疗"行业"强于大市"的评级，认为该行业在政策与产业共 振下正迎来加速发展。华大智造、华大基因、晶泰控股、英矽智能、联影智能、鹰瞳科技等多家行业内 企业获关注。 研报指出，全球AI医疗市场预计将从2022年的137亿美元迅猛增长至2030年的1553亿美元。政策层面， 国家多部门联合推动"人工智能+制造"，重点鼓励AI在高端医疗装备等场景的应用，为行业注入强心 剂。同时，海外领先企业如TempusAI业绩高增、英伟达与礼来巨额投资共建AI实验室等动向，也强化 了全球产业高景气度的预期。 报告分析，AI技术已在制药、辅助诊断、影像手术及医疗服务等多个医疗细分领域步入成熟。在辅助 诊断方向，具备高质量数据与技 ...

Group 1: Healthcare Sector - The domestic brain-computer interface (BCI) market is expected to maintain double-digit growth, with a projected market size of 3.83 billion yuan in 2025, reflecting a 20% year-on-year increase [3][11] - The global BCI market is anticipated to reach 2.93 billion USD in 2025, marking a 12% year-on-year growth [3][11] - The Chinese government has introduced several significant policies since 2025 to support the development of BCIs in the medical field, including the inclusion of BCIs in medical insurance [11][12] - As of December 2025, there have been 24 financing rounds in the domestic BCI sector, totaling over 5 billion yuan, with a record single financing of 350 million yuan in February 2025 [3][15] Group 2: High-end Manufacturing Sector - The excavator market in China showed a mild recovery, with total sales of 23,095 units in December 2025, representing a 19.2% year-on-year increase [22][23] - For the entire year of 2025, excavator sales reached 235,257 units, up 17% from the previous year, with domestic sales increasing by 17.9% and exports by 16.1% [22][24] - The adjustment of export tax rebates for photovoltaic products is expected to accelerate industry clearing and benefit product price recovery [27][28] Group 3: Market Overview - The A-share market experienced a general increase, with the Shanghai Composite Index rising by 3.82% during the week of January 5-9, 2026 [29][30] - The average daily trading volume in the market was 2.85 trillion yuan, showing an increase compared to the previous week [29][30] - The performance of various sectors was mixed, with growth and cyclical sectors leading the gains, while some sectors like banking and transportation lagged behind [30][36]

中邮证券发布研报称，2026年初政策支持与海外AI医疗公司高增长表现，共同催化"AI+医疗"产业机 遇。据预测，2030年全球市场规模有望达1553亿美元，中国将快速增长至168亿美元。AI在制药、医疗 影像、辅助诊疗等领域正步入成熟应用，推动产业链价值提升，医疗AI三类证审批加速进一步助力行 业持续扩张。 中邮证券主要观点如下： 政策及板块热点共振，"AI+医疗"有望迎来加速 政策面：2026年1月7日，国家工业和信息化部等八部门联合印发了《"人工智能+制造"专项行动实施意 见》提出要"推动智能装备迭代"，重点提及AI在高端医疗装备、远程医疗等场景应用，相关领域有望显 著受益于政策驱动。 "AI+医疗"市场有望超千亿美元，板块享受估值溢价 市场空间方面，"AI+医疗"行业人工智能解决方案的全球市场规模预计将由2022年的137亿美元增至 2030年的1553亿美元，CAGR为35.5%，中国市场至2030年有望达到168.3亿美元，行业存在爆发式增长 机会。在国内政策导向下，医疗AI三类证审批加速，截至2025年12月5日，累计已有207款人工智能医 疗器械获三类医疗器械注册证，其中，2025年以来新增获批 ...

Core Insights - BGI Genomics and Roche Diagnostics have launched Alzheimer's disease tests in China to enhance access to user-friendly diagnostic and monitoring options for patients [1] Company Developments - BGI Genomics and Roche Diagnostics are collaborating to provide new testing solutions for Alzheimer's disease in the Chinese market [1] Industry Trends - The introduction of these tests reflects a growing trend in the healthcare industry towards improving diagnostic capabilities and patient monitoring for neurodegenerative diseases [1]

行业相对指数表现（相对值） 强于大市 |维持 行业基本情况 | | 收盘点位 | 8787.25 | | --- | --- | --- | | 52 | 周最高 | 9323.49 | | 52 | 周最低 | 6790.4 | 2025-01 2025-03 2025-06 2025-08 2025-10 2026-01 -4% 0% 4% 8% 12% 16% 20% 24% 28% 32% 36% 医药生物 沪深300 资料来源：聚源，中邮证券研究所 证券研究报告：医药生物|点评报告 行业投资评级 l AI 在制药、辅助诊断、医疗服务等领域步入成熟阶段 在制药领域，凭借 AI 技术平台强大的数据分析和模型预测能力， 相关公司在分子设计和药物筛选方面能够大幅提升药物的研发效率 和成功率。AI 制药公司通过和大型药企合作共同推动管线进展，涉及 计算机、物理、化学、生物、临床等交叉领域，管线推进越靠后，价 值量显著增高。在影像/手术领域：AI 通过在医疗影像分析方向深度 学习，能够快速识别病灶，实现精准诊断；AI 亦能辅助术前及术中及 时规划，并提供综合解决方案。在辅助诊断领域，主要参与者为数据 驱动型平台 ...

Core Insights - The article discusses the intersection of artificial intelligence and healthcare, particularly focusing on the potential for AI to significantly extend human lifespan and improve health outcomes [1] - It highlights a conversation between Yinye, CEO of BGI Group, and AI expert Du Lan, exploring the concept of a trillion-dollar health and longevity economy [1] Group 1 - The dialogue emphasizes that the real competition is not AI itself, but those who utilize AI effectively [1] - The article suggests a transformative shift in human health, moving from a focus on terminal illnesses like cancer to managing chronic diseases, potentially allowing people to live up to 150 years [1] - It indicates a future where advancements in science and AI could fundamentally alter the trajectory of human life expectancy and quality of life [1]

Group 1 - The A-share market experienced overall fluctuations on January 13, with the medical device ETF (562600) rising by 1.05%, marking its fourth consecutive day of gains [1] - AI medical applications continued to show strength, with notable stock increases: Tianzhihang up 16.62%, Dian Diagnostics up 11.9%, Berry Genomics up 9.97%, and Jiukang Bio up 9.41% [1] - The trading volume of the medical device ETF (562600) reached 66.1453 million yuan, indicating a significant increase in trading activity [1] Group 2 - The brain-computer interface industry in China is emerging as a trillion-yuan ecosystem, with the medical device ETF (562600) tracking the CSI Medical Device Index, which has a 23.8% allocation to brain-computer interfaces, the highest among listed ETFs [2] - The medical device sector constitutes 89.2% of the ETF, highlighting its concentrated focus and ability to capture growth opportunities in niche markets [2] - Investors can also consider the Huaxia CSI Medical Device ETF Initiated Link A (021250) and Huaxia CSI Medical Device ETF Initiated Link C (021251) for convenient investment options [2]

Group 1: Market Overview - The A-share market experienced a collective pullback on January 13, with the Shanghai Composite Index down 0.64%, ending a 17-day winning streak, while the Shenzhen Component Index fell 1.37% and the ChiNext Index dropped 1.96% [1] - The trading volume in the Shanghai, Shenzhen, and Beijing markets exceeded 3.6 trillion yuan, marking a slight increase from the previous day and setting a new historical high [1] Group 2: AI Medical Sector - The AI medical sector continues to thrive, with significant gains; the Hong Kong medical ETF (159137) surged by 3.44% and reached a near-limit-up level, while the largest A-share medical ETF (512170) hit a three-month high with a peak increase of 3.67% [4][6] - AI medical concept stocks saw substantial increases, with Ark Health rising over 76% after announcing a collaboration with Tencent Health on an "AI + chronic disease management" plan [4][8] Group 3: Banking Sector - The banking sector showed resilience, with several banks like Ningbo Bank and Hangzhou Bank seeing gains of over 4% and 3% respectively, while the top banking ETF (512800) rose by 0.37% [11][13] - The first bank executive buyback announcement of 2026 was made by Chongqing Rural Commercial Bank, indicating confidence in the company's fundamentals [13] - Historical data suggests that the banking sector tends to perform well before the Spring Festival, with an average absolute return of 4.4% [16] Group 4: Commercial Aerospace Sector - The commercial aerospace sector faced volatility, with the general aviation ETF (159231) experiencing a significant drop of 7.27%, despite a net inflow of 46 million yuan on the same day [18][19] - The sector's performance has been mixed, with 44 out of 50 component stocks declining, while some stocks like Tianyin Electromechanical and Haige Communication saw gains [18] Group 5: Future Outlook - Analysts suggest that the current market liquidity is ample, and thematic trading is expected to continue, with a focus on the "Musk Chain" and non-bank financial investment opportunities [3] - The market is anticipated to exhibit structural opportunities, with a theme-driven approach and rapid capital rotation among different industry lines [3]